Related Experiment Video

Updated: Mar 29, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

88.4K

[Newborn screening : the point of view of the paediatrician]

C De Laet, H Laeremans, A Ferster

    Revue Medicale De Bruxelles
    |November 24, 2015
    PubMed

    Insights

    Newborn screening programs, crucial for public health, vary globally. Future advancements like whole genome sequencing promise expanded screening but raise ethical considerations.

    Area of Science:

    • Public Health
    • Genetics
    • Neonatal Care

    Background:

    • Newborn screening significantly improves outcomes for congenital diseases.
    • International variations in screening panels are influenced by demographic, epidemiological, and economic factors.

    Purpose of the Study:

    • To outline the current newborn screening program in the French Community of Belgium.
    • To discuss the complexities and future evolution of newborn screening.

    Main Methods:

    • The Belgian program screens for 13 metabolic and endocrine diseases, hearing loss, and hemoglobinopathies.
    • The process involves parent information, sample collection, laboratory analysis, result follow-up, care initiation, and genetic counseling.

    Main Results:

    • The described newborn screening process is comprehensive, involving multiple stakeholders.
    • The program in the French Community of Belgium targets specific congenital conditions.

    Conclusions:

    • Newborn screening is a multifaceted public health initiative requiring stakeholder collaboration.
    • Future screening may incorporate whole genome sequencing, presenting both opportunities and ethical challenges that necessitate proactive preparation.

    More Related Videos

    Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus06:15

    Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

    Published on: March 6, 2019

    52.8K
    State of the Art Cranial Ultrasound Imaging in Neonates10:02

    State of the Art Cranial Ultrasound Imaging in Neonates

    Published on: February 2, 2015

    26.6K

    Related Concept Videos

    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    373
    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
    704
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
    330
    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
    462
    Drug Dosing: Infants and Children01:29

    Drug Dosing: Infants and Children

    Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
    744